Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines
Prostate Cancer, Version 1.2014 Featured Updates to the NCCN Guidelines
复制标题
DOI：
10.6004/jnccn.2013.0174
复制
发表时间：
2013-12-01
影响因子：
13.4
通讯作者：
Ho, Maria
中科院分区：
文献类型：
--
作者：
Mohler, James L.;Kantoff, Philip W.;Ho, Maria
NCCN 前列腺癌指南为前列腺癌患者的临床管理提供多学科建议。本报告重点介绍了近期值得注意的更新。二氯化镭 223 是一种一流的放射性药物，最近被批准用于治疗有症状的骨转移且无已知内脏疾病的患者。它作为一线和二线选项均获得 1 类推荐。 NCCN 前列腺癌专家组还根据最近的 III 期临床数据，比较非转移性和转移性环境中的 2 种策略，修订了关于间歇性或连续性雄激素剥夺治疗选择的建议。
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.